Loading...
•
Dec 31, 2021
Liquidia Q4 2021 Earnings Report
Reported full-year financial results and provided a corporate update.
Key Takeaways
Liquidia Corporation reported its full-year 2021 financial results, highlighting the tentative FDA approval of YUTREPIA and the expansion of Treprostinil Injection use. The company is preparing to launch YUTREPIA in late 2022, pending final FDA approval.
Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder.
Expanded use of Treprostinil Injection to include subcutaneous administration.
Preparing to launch YUTREPIA in late-2022 pending final FDA approval.
Completed first full year as a fully integrated, research, development, and commercial organization.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...